Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

WIB_icon

Is Post-Discharge VTE Prophylaxis Necessary for Patients With COVID-19?

In hospitalized patients with COVID-19, the risk of venous thromboembolism (VTE) following discharge was not significantly greater compared with the VTE risk in patients...

The Year in FDA Approvals

Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...

Rivaroxaban and Standard Anticoagulants Safe, Reduce Clot Burden in Most Children With CVC-VTE

In most children with central venous catheter-related venous thromboembolism (CVC-VTE), treatment with rivaroxaban or other standard anticoagulants reduced clot burden, according to results from...
You Make the Call

You Make the Call: Is 3 months of anticoagulation enough for a provoked VTE?

This month, Keith McCrae, MD, discusses the appropriate length of anticoagulation for a provoked DVT. And don't forget to check out next month's clinical dilemma...
You Make the Call

Reader Responses: Is 3 months of anticoagulation enough for a provoked VTE?

Here’s how readers responded to a You Make the Call question about the appropriate length of anticoagulation for a provoked DVT. Disclaimer: ASH does not...
On location

Is It Time for a Paradigm Shift for CAPS Treatment?

Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic antiphospholipid syndrome (CAPS), according to research presented at the...
On location

DVT Increases Health-Care Burden and Mortality in Patients with Cancer

Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality, are less frequently treated with thrombolysis, and experience gastrointestinal...

Apixaban Noninferior to Subcutaneous Dalteparin for Cancer-Associated VTE

Results from the CARAVAGGIO trial showed the direct oral anticoagulant apixaban was as effective as dalteparin, a type of low-molecular-weight heparin, in preventing recurrent...
WIB_icon

Twice-Daily Low-Dose Aspirin Improves Antiplatelet Response in Essential Thrombocythemia

Once-daily aspirin 75 to 100 mg is the current recommended antithrombotic regimen for patients with essential thrombocythemia (ET), but once-daily aspirin may not be...

FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131

The FDA has granted orphan drug designations to two therapies for hematologic conditions. The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...
Advertisement

Current Issue

October 2020 Volume 6, Issue 12

This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.

Block title